Business
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit SCOPE Genotype Predictor, an AI-powered
About this update from Lunit Inc.
[{"type":"text","content":"AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC","length":195,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit SCOPE Genotype Predictor, an AI-powered deep learning model capable of predicting EGFR mutations directly from hematoxylin and eosin (H&E)-stained tissue samples in NSCLC patients, will be presented in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).","length":776,"tagName":"p"},{"type":"image","alt":"At AACR 2025, Lunit will showcase its latest AI-driven approach to predicting EGFR mutations in NSCLC—in collaboration with AstraZeneca.","displaySize":"","headline":null,"caption":"At AACR 2025, Lunit will showcase its latest AI-driven approach to predicting EGFR mutations in NSCLC—in collaboration with AstraZeneca.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":222,"url":"https://media.zenfs.com/en/prnewswire.com/3e8af3c437fa0d78053f732b316ea3a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fR1bkPOmJH81TFP9rATUow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3e8af3c437fa0d78053f732b316ea3a7","width":400,"height":222}},"href":"https://mma.prnewswire.com/media/2650494/At_AACR_2025_Lunit_showcase_latest_AI_driven_approach_predicting_EGFR.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"EGFR mutation testing plays a crucial role in determining the best course of treatment for patients with NSCLC, yet many patients remain untested due to logistical and resource constraints, despite guideline recommendations. Existing AI models designed to predict mutations from pathology images have faced limitations in real-world clinical applications due to limited t...